{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:10:11Z","timestamp":1760645411669},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1007\/s11910-003-0036-7","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T12:26:57Z","timestamp":1180700817000},"page":"46-51","source":"Crossref","is-referenced-by-count":3,"title":["New strategies for prevention of ischemic stroke: The life study"],"prefix":"10.1007","volume":"3","author":[{"suffix":"Jr.","given":"Harold P.","family":"Adams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"36_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7336.S71","volume":"324","author":"Antithrombotic Trialist\u2019s Collaboration","year":"2002","unstructured":"Antithrombotic Trialist\u2019s Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71\u201386.","journal-title":"BMJ"},{"key":"36_CR2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.STR.28.5.946","volume":"28","author":"GJ Blauw","year":"1997","unstructured":"Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG: Stroke, statins, and cholesterol. Stroke 1997, 28:946\u2013950.","journal-title":"Stroke"},{"key":"36_CR3","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1161\/01.CIR.92.9.2419","volume":"922","author":"RP Byington","year":"1995","unstructured":"Byington RP, Jukema JW, Salonen JT, et al.: Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995, 922:2419\u20132425.","journal-title":"Circulation"},{"key":"36_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jama.278.4.313","volume":"278","author":"PR Hebert","year":"1997","unstructured":"Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997, 278:313\u2013321.","journal-title":"JAMA"},{"key":"36_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0021-9150(98)00014-8","volume":"138","author":"JR Crouse","year":"1998","unstructured":"Crouse JR, Byington RP, Furberg CD: HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998, 138:11\u201324.","journal-title":"Atherosclerosis"},{"key":"36_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145\u2013153.","journal-title":"N Engl J Med"},{"key":"36_CR7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/S0140-6736(01)06226-2","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001, 358:1026\u20131027.","journal-title":"Lancet"},{"key":"36_CR8","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","volume":"356","author":"B Neal","year":"2000","unstructured":"Neal B, MacMahon S, Chapman N: Blood Pressure Lowering Treatment Trialist\u2019s Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955\u20131964.","journal-title":"Lancet"},{"key":"36_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, et al., for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995\u20131003. Important study.","journal-title":"Lancet"},{"key":"36_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","volume":"359","author":"LH Lindholm","year":"2002","unstructured":"Lindholm LH, Ibsen H, Dahl\u00f6f B, et al., for the LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004\u20131010. Important study.","journal-title":"Lancet"},{"key":"36_CR11","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.45.4.659","volume":"45","author":"RL Sacco","year":"1995","unstructured":"Sacco RL: Risk factors and outcomes for ischemic stroke. Neurology 1995, 45:S10-S14.","journal-title":"Neurology"},{"key":"36_CR12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/oxfordjournals.aje.a117595","volume":"142","author":"E Lindenstrom","year":"1995","unstructured":"Lindenstrom E, Boysen G, Nyboe J: Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study. Am J Epidemiol 1995, 142:1279\u20131290.","journal-title":"Am J Epidemiol"},{"key":"36_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","volume":"335","author":"S MacMahon","year":"1992","unstructured":"MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1992, 335:765\u2013774.","journal-title":"Lancet"},{"key":"36_CR14","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/archinte.152.5.938","volume":"152","author":"SJ Phillips","year":"1992","unstructured":"Phillips SJ, Whisnant JP: Hypertension and the brain. The National High Blood Pressure Education Program. Arch Intern Med 1992, 152:938\u2013945.","journal-title":"Arch Intern Med"},{"key":"36_CR15","doi-asserted-by":"publisher","first-page":"20R","DOI":"10.1016\/S0002-9149(98)00752-8","volume":"82","author":"JA Staessen","year":"1998","unstructured":"Staessen JA, Thijs L, Gasowski J, Cells H, Fagard RH: Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in TEurope (Syst-Eur) trial. Am J Cardiol 1998, 82:20R-22R.","journal-title":"Am J Cardiol"},{"key":"36_CR16","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/00004872-199917030-00001","volume":"17","author":"L Hansson","year":"1999","unstructured":"Hansson L: The Hypertension Optimal Treatment Study and the importance of lowering blood pressure. J Hypertens 1999, 17(suppl):S9\u201313.","journal-title":"J Hypertens"},{"key":"36_CR17","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jama.275.20.1571","volume":"275","author":"WB Kannel","year":"1996","unstructured":"Kannel WB: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996, 275:1571\u20131576.","journal-title":"JAMA"},{"key":"36_CR18","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1161\/01.STR.30.7.1312","volume":"30","author":"OH Klungel","year":"1999","unstructured":"Klungel OH, Stricker BH, Paes AH, et al.: Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Stroke 1999, 30:1312\u20131318.","journal-title":"Stroke"},{"key":"36_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","volume":"356","author":"L Hansson","year":"2000","unstructured":"Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359\u2013365.","journal-title":"Lancet"},{"key":"36_CR20","doi-asserted-by":"publisher","first-page":"1L","DOI":"10.1016\/S0002-9149(01)01878-1","volume":"88","author":"VJ Dzau","year":"2001","unstructured":"Dzau VJ, Bernstein K, Celermajer D, et al., for the Working Group on Tissue Angiotensin-converting enzyme, International Society of Cardiovascular Pharmacotherapy: The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001, 88:1L-20L.","journal-title":"Am J Cardiol"},{"key":"36_CR21","doi-asserted-by":"publisher","first-page":"264S","DOI":"10.1016\/S0895-7061(01)02152-5","volume":"14","author":"GL Bakris","year":"2002","unstructured":"Bakris GL: Angiotensin-converting enzyme inhibition to enhance vascular health-clinical and research models. Am J Hypertens 2002, 14:264S-269S.","journal-title":"Am J Hypertens"},{"key":"36_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/09537100120058793","volume":"12","author":"IF Islim","year":"2001","unstructured":"Islim IF, Bareford D, Beevers DG: A single (investigator)-blind randomised control trial comparing the effects of quinapril and mifedipine on platelet function in patients with mild to moderate hypertension. Platelets 2001, 12:274\u2013278.","journal-title":"Platelets"},{"key":"36_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1210\/er.22.1.36","volume":"22","author":"J Calles-Escandon","year":"2001","unstructured":"Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Rev 2001, 22:36\u201352.","journal-title":"Endocrine Rev"},{"key":"36_CR24","first-page":"S66","volume":"9","author":"BD Myers","year":"1998","unstructured":"Myers BD, Boothroyd D, Olshen RA: Angiotensin-converting enzyme inhibitor for slowing progression of diabetic and nondiabetic kidney disease. J Am Soc Nephrol 1998, 9:S66-S70.","journal-title":"J Am Soc Nephrol"},{"key":"36_CR25","first-page":"S24","volume":"32","author":"C Borghi","year":"1998","unstructured":"Borghi C, Ambrosioni E: Evidence-based medicine and ACE inhibition. J Cardiovasc Pharmacol 1998, 32:S24-S35.","journal-title":"J Cardiovasc Pharmacol"},{"key":"36_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S0003-4975(01)02779-5","volume":"72","author":"HL Lazar","year":"2001","unstructured":"Lazar HL, Bao Y, Rivers S, Colton T, Bernard SA: High tissue affinity angiotensin-converting enzyme inhibitors improve endothelial function and reduce infarct size. Ann Thoracic Surg 2001, 72:548\u2013553.","journal-title":"Ann Thoracic Surg"},{"key":"36_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/00004872-199816040-00006","volume":"16","author":"S Taddei","year":"1998","unstructured":"Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A: Effects of angiotensin converting enzyme inhibition on endotheliumdependent vasodilatation in essential hypertensive patients. J Hypertens 1998, 16:447\u2013456.","journal-title":"J Hypertens"},{"key":"36_CR28","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00005344-200109011-00004","volume":"37","author":"F Enseleit","year":"2001","unstructured":"Enseleit F, Hurlimann D, Luscher TF: Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol 2001, 37:S21-S30.","journal-title":"J Cardiovasc Pharmacol"},{"key":"36_CR29","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.2337\/diacare.24.12.2091","volume":"24","author":"L Niskanen","year":"2001","unstructured":"Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, for the The CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic\/ beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001, 24:2091\u20132096.","journal-title":"Diabetes Care"},{"key":"36_CR30","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1161\/hs0302.103657","volume":"33","author":"PB Gorelick","year":"2002","unstructured":"Gorelick PB: Stroke prevention therapy beyond antithrombotics. Unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke 2002, 33:862\u2013875.","journal-title":"Stroke"},{"issue":"suppl 1","key":"36_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000047784","volume":"13","author":"MJ Alberts","year":"2002","unstructured":"Alberts MJ: Secondary prevention of stroke and the expanding role of the neurologist. Cerebrovasc Dis 2002, 13(suppl 1):12\u201316.","journal-title":"Cerebrovasc Dis"},{"key":"36_CR32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1212\/WNL.54.4.790","volume":"54","author":"DC Hess","year":"2000","unstructured":"Hess DC, Demchuk AM, Brass LM, Yatsu FM: HMG-CoA reductase inhibitors (statins). A promising approach to stroke prevention. Neurology 2000, 54:790\u2013796.","journal-title":"Neurology"},{"key":"36_CR33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/01.ATV.20.2.538","volume":"20","author":"M Pyorala","year":"2000","unstructured":"Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K: Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000, 20:538\u2013544.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"36_CR34","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/aje\/152.10.897","volume":"152","author":"PA Sakkinen","year":"2000","unstructured":"Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000, 152:897\u2013907.","journal-title":"Am J Epidemiol"},{"key":"36_CR35","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.2337\/diabetes.50.10.2396","volume":"50","author":"J Pihlajamaki","year":"2001","unstructured":"Pihlajamaki J, Austin M, Edwards K, Laakso M: A major gene effect on fasting insulin and insulin sensitivity in familial combined hyperlipidemia. Diabetes 2001, 50:2396\u20132401.","journal-title":"Diabetes"},{"key":"36_CR36","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.2337\/diabetes.50.10.2316","volume":"50","author":"AL Hevener","year":"2001","unstructured":"Hevener AL, Reichart D, Janez A, Olefsky J: Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats. Diabetes 2001, 50:2316\u20132322.","journal-title":"Diabetes"},{"key":"36_CR37","first-page":"13","volume":"121","author":"U Smith","year":"2001","unstructured":"Smith U: Pioglitazone: mechanism of action. Int J Clin Pract 2001, 121(suppl):13\u201318.","journal-title":"Int J Clin Pract"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-003-0036-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-003-0036-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-003-0036-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-003-0036-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T17:05:00Z","timestamp":1581959100000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-003-0036-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1007\/s11910-003-0036-7","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}